Partial
Partially Aligned
Patient Risk:
Moderate
Summary
One clinical effectiveness-related claim is supported by the provided label text, but multiple claims about patient assistance/savings program details are not supported by the provided FDA-approved label sections.
Category Scores
Accurate Statements
Vascepa has been shown to effectively lower triglyceride levels.
Supported by 1 INDICATIONS AND USAGE (adjunct to diet to reduce TG levels; adjunct to maximally tolerated statin therapy to reduce risk in patients with elevated TG) and 14.2 Severe Hypertriglyceridemia (reduced median TG from baseline vs placebo).
Unsupported Statements
Amarin's Vascepa Patient Assistance Program provides eligible patients with free Vascepa for up to one year.
Patient assistance program details are not present in the provided label sections.
The Patient Access Network (PAN) Foundation provides financial assistance to patients with high triglycerides, including those taking Vascepa.
PAN Foundation information is not present in the provided label sections.
The Vascepa Savings Card offers eligible patients a discount on their Vascepa prescription.
Savings card/discount program information is not present in the provided label sections.
Some Vascepa assistance programs may have restrictions on how often patients can apply, such as a maximum of one application per year.
No assistance program application-frequency restrictions are present in the provided label sections.
Vascepa assistance programs have eligibility requirements that may include income limits, insurance status, and medical history.
No assistance program eligibility criteria are present in the provided label sections.
If a patient is not eligible for one Vascepa assistance program, they may be eligible for another.
No cross-program eligibility statement is present in the provided label sections.
Vascepa assistance programs may be unable to accept new applications if a program is fully funded.
No funding/acceptance restrictions are present in the provided label sections.
Vascepa is a prescription medication.
No explicit prescription-status statement is present in the provided label sections.
Contradictions
Important Omissions
No label-supported dosage, indication context (including specific populations/criteria), contraindications, warnings/precautions, monitoring, or administration instructions were provided in the claims list, preventing assessment of labeling accuracy for these areas.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The unsupported claims concern financial assistance/savings program logistics rather than clinical safety. However, they are not substantiated by the provided FDA-approved label sections, reducing labeling alignment and potentially misleading regarding access/coverage details.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple programmatic claims (patient assistance/savings card details and eligibility/application/funding restrictions) are not supported by the provided FDA-approved label sections.
Suggested Improvement
Limit claims to label-supported clinical information (e.g., TG reduction indication statements) and remove or clearly separate non-label promotional/access-program details unless the full label includes them.